Skip directly to content



















1. Inserto de producto aprobado: LLD_Per_USPI_28Sep2018_v1
2. Finn RS, Martin M, Rugo HS, et al. Palbociclib and letrozole in advanced breast cancer. NEJM 2016;375(20):1925-1936
3. Cristofanilli M, Turner NC, Bodarenko I, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol. 2016; 17(4):425-439. 
4. Rugo HS, Finn RS, Diéras V, et al. Palbociclib Plus Letrozole as First-Line Therapy in Estrogen Receptor-Positive/Human Epidermal Growth Factor Recep- Breast Cancer Symposium (SABCS); December 5-9, 2017; San Antonio, TX, USA. 
5. Rugo HS, et al. ESMO 2016: poster 2627.
6.Durairaj Ch, Ruiz-Garcia A, Gauthier E, et al. Palbociclib has no clinically relevant effect on the QTc interval in patients with advanced breast cancer. Anti-Cancer Drugs 2018; 29:271-280. 
7. Harbeck et al. Annals of Oncology 2016; 27: 1047-1054. 
8. Turner NC, et al. SABCS 2016; poster P4-22-06. 
9. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Breast Cancer V3.2019. National Comprehensive Cancer Network, Inc 2019. All rights reserved.02019 version accesed Nov 12, 2019. To view the most recent and complete version of the NCCN Guidelines, go online to NATIONAL  Comprehensive Cancer Inc All reserved. version accessed Nov To the most recent and version the NCCN online to NATIONAL CANCER NCCN, NCCN and all other NCCN Content are ovvned the National Cancer Inc. 
10. Finn RS, Crown JP, Lang I, et al. The cyclin-dependent kinase 4/6 inhibitor Palbociclib in combination with letrozole versus letrozole alone as first line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomized phase 2 study. Lancet Oncol 2015;16(1):25-35.



Registro Sanitario IBRANCE® 75mg Cápsulas: EE03015 Pfizer S.A

Registro Sanitario IBRANCE® 100mg Cápsulas: EE03030 Pfizer S.A

Registro Sanitario IBRANCE® 125mg Cápsulas: EE03014 Pfizer S.A